TG Therapeutics, Inc.NASDAQ: TGTX

TG Therapeutics Announces Pivotal Data from the UNITY-CLL and UNITY-NHL Clinical Trials Presented at the 62nd American Society of Hematology Annual Meeting

· Issued by TG Therapeutics, Inc.

UNITY-CLL: U2 significantly improved progression-free survival over obinutuzumab plus chlorambucil (HR=0.54, p

TG Therapeutics, Inc. on 6ix

Story so far

Earlier from TG Therapeutics

Later from TG Therapeutics

All TG Therapeutics news releases